Hikma's US facility back in compliance

Hikma Pharmaceuticals (LSE: HIK), Jordan's largest pharmaceutical company, has received a close-out letter from the US Food and Drug Administration that lifts the warning letter received in February 2012 in respect of its Eatontown facility in New Jersey, which provides oral products for the US market.

This communication follows the US FDA’s re-inspection of the facility in February 2014 to complete its evaluation of the corrective actions the company took in response to the warning letter. This successfully resolves all issues raised by the FDA in February 2012 and all subsequent communications.

Said Darwazah, Hikma chief executive, commented: “I am pleased to report that we have brought the Eatontown facility back into compliance with the US FDA. The investment we have made to complete the remediation work, upgrade our manufacturing processes and strengthen our operations, provides greater quality and support for our customers and we are committed to continuing to invest in the highest quality standards. We are gradually re-introducing products to the US market from the Eatontown facility, adding to the products we supply from our US FDA approved facilities in Jordan and Saudi Arabia. We believe there are an increasing number of attractive market opportunities for our Generics business and we are investing in our pipeline of oral and other non-injectable product forms, whilst continuing to look for further product acquisition opportunities.”